Strategic Partnerships Genfit is a publicly traded biopharma with a diversified liver disease pipeline and global footprint, presenting multiple collaboration opportunities with pharma, diagnostic developers, and CROs across France, Switzerland, the US, and beyond.

Diagnostic Expansion Genfit’s NIS4 based NASHnext diagnostic offers via Labcorp OnDemand expands access to MASH identification, enabling potential partnerships with diagnostic labs, payers, and physician networks to drive adoption and volume.

Clinical Pipeline A broad ACLF program in Phase 2 plus PBC and cholangiocarcinoma efforts indicate opportunities to co-develop combination strategies, companion diagnostics, or regulatory collaborations to accelerate late-stage assets.

Financial Readiness With a cash position and revenue stream in the tens of millions and Ipsen holding a material stake, Genfit may entertain licensing, milestone-based partnerships, or strategic investments to fund pipeline acceleration.

Market Positioning Genfit’s B Corp certification and focus on high unmet needs in rare liver diseases position it well for value-based partnerships with healthcare systems, patient advocacy groups, and payers seeking proven clinical and societal impact.